The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...
InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the ...
The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus erythematosus.
That’s what the autoimmune disease lupus does, 1 and when it strikes, it can cause significant symptoms, including extreme ...
The FDA has approved a self-administered autoinjector form of anifrolumab for the treatment of systemic lupus erythematosus, ...
AstraZeneca’s Saphnelo approved in US for subcutaneous self-administration as a new autoinjector to treat systemic lupus erythematosus: Cambridge, UK Tuesday, April 28, 2026, 10 ...
The U.S. Food & Drug Administration (FDA) has granted approval for subcutaneous administration of anifrolumab (SAPHNELO) for ...
Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in ...
Fatimah Shepherd’s kidneys were compromised, and pregnancy could send her into kidney failure. By Roni Caryn Rabin ...
AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector ...
Weight-based dosing misses accounting for factors such as chronic kidney disease or chronic transaminitis, which could ...
In a new analysis of Phase 2 and 3 anifrolumab (Saphnelo®) clinical trial data, researchers found that the SLE Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results